Jingtai Technology and EDDC re sign cooperation to continuously empower biopharmaceutical research and development with robots and large language mode
2023-11-22
Recently, Jingtai Technology announced the signing of a memorandum of cooperation with the Experimental Drug Development Center (EDDC), a national drug development platform in Singapore, to expand cooperation in the fields of automated synthesis experiments and large language models for drug discovery. Based on the AI+robot driven non-small cell lung cancer drug research and development cooperation agreement signed in 2022, under this cooperation memorandum, both parties will focus on promoting the accelerated transformation of scientific research achievements into pipeline assets, and jointly promote the automation and intelligent upgrading of drug research and development.
In the new cooperation, Jingtai Technology and EDDC will expand their cooperation in the fields of automated chemical synthesis and AI drug design, exploring how to integrate Jingtai Technology's automated library synthesis, drug research and development synthesis services, and other solutions into the development of EDDC. Jingtai's large-scale automated robot laboratory can remotely support the research and development experimental needs of EDDC and generate high-quality data in batches, further strengthening EDDC's drug research and development capabilities. Through the integration of robot experiments and AI, advanced algorithms and industrial practices in this field are developed and explored.
Jingtai Technology will also explore potential projects with EDDC to use advanced AI algorithms such as big language models for drug research and development. The two companies will combine high-throughput and automated cutting-edge experimental technologies to explore the potential value of cell phenotype and multi omics data, in order to gain a new perspective with richer data and develop AI and data-driven new technologies and research methods in the fields of target discovery and molecular design. This cooperation will fully utilize the technological advantages of Jingtai Technology in AI technology and the accumulated experience of EDDC in research and development data, preclinical, and clinical research.
Dr. Gu Liang, Chief Technology Officer of Jingtai Technology, stated that, As an innovative platform based enterprise, Jingtai is committed to empowering industry partners with the digital twin research and development system of AI+robots. EDDC has a strong scientific team and diverse research pipelines, while Jingtai Technology's independently developed automated synthesis laboratory is specially designed for complex and ever-changing exploratory experimental tasks in drug discovery. It can not only accompany the continuous growth of EDDC pipelines, but also accumulate large-scale standardized research for EDDC Send data and make important arrangements for more advanced intelligent technologies such as large models to drive scientific research. Looking forward to our deeper cooperation, which can help EDDC continuously shorten the cycle of transforming biological research results into clinical drugs with higher experimental flux, efficiency, and success rate, so that more high-quality and efficient drugs can benefit patients in Asia and even the world as soon as possible. “
Dr. Hao Weidong, Chief Scientific Officer of EDDC, said, "We are very pleased to join hands with Jingtai Technology to embark on this journey, leveraging Jingtai's automated experimental resources and AI capabilities to enhance our knowledge and skills in drug discovery and development. Through this partnership, we hope to further accelerate EDDC's drug discovery process and achieve our goal of providing innovative therapies for patients worldwide more quickly
Karmin Electronic (HK) Limited 
Hong Kong Tel:852-39070580 96557277
Hong Kong Fax:852-39070581
Email：
Hong Kong address: Room 6, 11th floor, Huali industrial center, 10 - 14guidi street, Fo Tan, New Territories, Hong Kong